San Diego—The liposomal, fixed-dose combination of cytarabine and daunorubicin, known as CPX-351, improves survival after hematopoietic cell transplant (HCT) in older patients with high-risk, previously untreated, secondary acute myeloid leukemia (AML), according to data from a Phase III trial.
Coupled with an early-phase study that showed favorable response rates with an antibody–drug conjugate called vadastuximab (SGN:CD-33A, Seattle Genetics) in younger patients with previously